Calcimedica Inc (CALC) Stock Price, Quote & News

Company Profile

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also d...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 952 5500

Website: calcimedica.com

Address:

505 Coast Boulevard South, Suite 307, La Jolla, United States

ParkerPumps Aug. 23 at 8:23 AM

$CALC CalciMedica Inc is a clinical stage biotech with calcium channel inhibitor platform

0 · Reply

Arya2021 Aug. 22 at 9:11 PM

$CALCIFY.X $CALC only I have the real calculation and key to everywhere and not anything else, Only I have the real calculation to words. I made myself to the real calculator and register.

0 · Reply

vinkush1 Aug. 21 at 5:19 PM

$CALC adding little by little hella insider buys

0 · Reply

YouVSYou Aug. 21 at 4:54 PM

$CALC CALC insiders loading Inverse h&s Gaps above To $4

0 · Reply

pablo4 Aug. 21 at 4:06 PM

$CALC you are kidding me....MORE INSIDER BUYING JUST ANNOUNCED! https://www.sec.gov/Archives/edgar/data/1534133/000141588925022549/xslF345X05/form4-08212025_120801.xml https://www.sec.gov/Archives/edgar/data/1534133/000141588925022550/xslF345X05/form4-08212025_120804.xml Management surely feels they have a gold mine here. JMO

0 · Reply

pablo4 Aug. 19 at 5:51 PM

$CALC I don't remember ever seeing more regular insider buying....has gone on for many weeks. It only paused during the earning blackout period. Anyway, here's another form 4 just filed. The CBO again acquiring shares.....5076 added this time on 8/15 at 2.90. JMO https://www.sec.gov/Archives/edgar/data/1534133/000141588925022261/xslF345X05/form4-08192025_010801.xml

0 · Reply

pablo4 Aug. 19 at 4:50 PM

$CALC why do retailers keep selling a stock that all insiders have been buying steadily over recent months and at higher prices?

1 · Reply

pablo4 Aug. 18 at 4:05 PM

$CALC JUST FILED with SEC: MORE INSIDER BUYING last week....Chief Medical Officer https://www.sec.gov/Archives/edgar/data/1534133/000141588925022159/xslF345X05/form4-08182025_120801.xml When their window to buy has been open, CALC mgt has been steadily buying over the past couple of months or so.....they clearly are very optimistic about what's ahead. JMO

0 · Reply

OffComesTheShirt Aug. 15 at 6:52 PM

$CALC 11% Off Comes The Shirt

0 · Reply

LongCallStrike Aug. 13 at 11:56 AM

$CALC enough funding through mid ‘26. Everything if going as planned.

0 · Reply

CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Jul 8, 2025, 7:00 AM EDT - 6 weeks ago

CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

Jun 25, 2025, 7:00 AM EDT - 2 months ago

CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure

Jun 12, 2025, 7:00 AM EDT - 2 months ago

CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting

May 14, 2025, 7:00 AM EDT - 3 months ago

CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Apr 17, 2025, 7:00 AM EDT - 4 months ago

CalciMedica Announces Presentations at Upcoming Medical Meetings

Apr 1, 2025, 7:00 AM EDT - 5 months ago

CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference

Mar 27, 2025, 7:00 AM EDT - 5 months ago

CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates

Mar 5, 2025, 7:00 AM EST - 6 months ago

CalciMedica Secures Credit Facility for Up to $32.5 Million

Mar 4, 2025, 7:00 AM EST - 6 months ago

CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference

Feb 19, 2025, 7:00 AM EST - 6 months ago

CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference

Feb 3, 2025, 4:05 PM EST - 7 months ago

CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 14, 2025, 7:00 AM EST - 7 months ago

CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors

Nov 21, 2024, 8:00 AM EST - 9 months ago

CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 13, 2024, 7:00 AM EST - 10 months ago

CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

Nov 7, 2024, 7:00 AM EST - 10 months ago

CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer

Oct 30, 2024, 10:11 PM EDT - 10 months ago

CalciMedica Announces Pricing of Public Offering of Common Stock

Oct 30, 2024, 4:50 PM EDT - 10 months ago

CalciMedica Announces Proposed Public Offering of Common Stock

Oct 30, 2024, 7:00 AM EDT - 10 months ago

CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

Oct 28, 2024, 4:05 PM EDT - 10 months ago

CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Oct 16, 2024, 8:00 AM EDT - 11 months ago

CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

Sep 3, 2024, 8:00 AM EDT - 1 year ago

CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 12, 2024, 4:10 PM EDT - 1 year ago

CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

Jul 9, 2024, 7:30 AM EDT - 1 year ago

CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora™ in Severe Acute Kidney Injury (AKI)

Jul 8, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Announces Presentations at Two Upcoming Healthcare Investment Conferences

Jul 1, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Set to Join Russell Microcap® Index

Jun 27, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Jun 26, 2024, 4:05 PM EDT - 1 year ago

CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

May 13, 2024, 4:05 PM EDT - 1 year ago

CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

May 7, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024

Apr 24, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis

Mar 28, 2024, 7:00 AM EDT - 1 year ago

CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates

Mar 13, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Feb 28, 2024, 6:57 PM EST - 1 year ago

CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Feb 13, 2024, 8:00 AM EST - 1 year ago

CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury

Feb 7, 2024, 4:05 PM EST - 1 year ago

CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 22, 2024, 8:00 AM EST - 1 year ago

CalciMedica Announces Private Placement of up to Approximately $55 Million

Nov 9, 2023, 7:00 AM EST - 1 year ago

CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

Nov 2, 2023, 9:15 AM EDT - 1 year ago

CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition

Sep 6, 2023, 7:30 AM EDT - 2 years ago

CalciMedica Announces Upcoming Presentations and Events in September

Aug 31, 2023, 7:30 AM EDT - 2 years ago

CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023

Aug 9, 2023, 7:30 AM EDT - 2 years ago

CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Jun 12, 2023, 7:30 AM EDT - 2 years ago

CalciMedica Announces Relisting on Nasdaq

Jun 6, 2023, 7:30 AM EDT - 2 years ago

CalciMedica Announces Publication of Preclinical Data in Journal of Clinical Investigation (JCI) Insight Supporting the Development of CRAC Channel Inhibitors for Chronic Pancreatitis (CP)

May 23, 2023, 8:00 AM EDT - 2 years ago

Life Biosciences Expands Team with the Appointment of Ming Yang, Ph.D., as SVP of Research and Development

May 23, 2023, 7:30 AM EDT - 2 years ago

CalciMedica Expands Executive Team with New Appointments

May 15, 2023, 8:55 AM EDT - 2 years ago

CalciMedica Reports First Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

Mar 20, 2023, 4:25 PM EDT - 2 years ago

CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement

ParkerPumps Aug. 23 at 8:23 AM

$CALC CalciMedica Inc is a clinical stage biotech with calcium channel inhibitor platform

0 · Reply

Arya2021 Aug. 22 at 9:11 PM

$CALCIFY.X $CALC only I have the real calculation and key to everywhere and not anything else, Only I have the real calculation to words. I made myself to the real calculator and register.

0 · Reply

vinkush1 Aug. 21 at 5:19 PM

$CALC adding little by little hella insider buys

0 · Reply

YouVSYou Aug. 21 at 4:54 PM

$CALC CALC insiders loading Inverse h&s Gaps above To $4

0 · Reply

pablo4 Aug. 21 at 4:06 PM

0 · Reply

pablo4 Aug. 19 at 5:51 PM

0 · Reply

pablo4 Aug. 19 at 4:50 PM

$CALC why do retailers keep selling a stock that all insiders have been buying steadily over recent months and at higher prices?

1 · Reply

pablo4 Aug. 18 at 4:05 PM

0 · Reply

OffComesTheShirt Aug. 15 at 6:52 PM

$CALC 11% Off Comes The Shirt

0 · Reply

LongCallStrike Aug. 13 at 11:56 AM

$CALC enough funding through mid ‘26. Everything if going as planned.

0 · Reply

d_risk Aug. 13 at 6:16 AM

$CALC - CalciMedica, Inc. - 10Q - Updated Risk Factors CALC’s latest 10-Q risk factors shift focus to clinical and regulatory hurdles for Auxora, with new risks on trial data volatility, manufacturing, market acceptance, pricing, IP disputes, and global trade, while Nasdaq relisting and some stockholder influence risks are dropped. #Pharmaceuticals #MarketAcceptance #ManufacturingChallenges #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/CALC/10-Q/2025-08-12

0 · Reply

MrAlientrader Aug. 12 at 3:24 PM

$CALC nearly there

0 · Reply

WATSON2005 Aug. 12 at 2:45 PM

$CALC Any particular reason for the downturn? I thought I was getting a steal when I got in at $2.96...oh well.

0 · Reply

pablo4 Aug. 12 at 2:39 PM

$CALC this stock is crazy, IMO.

1 · Reply

MrAlientrader Aug. 11 at 8:32 PM

$CALC waiting for $2 back in

0 · Reply

MrAlientrader Aug. 4 at 7:50 PM

$CALC next round to $6

0 · Reply

towie Aug. 4 at 12:41 PM

$CALC is there any news?

0 · Reply

pablo4 Aug. 1 at 11:58 PM

$CALC Two factors...(1) the regular insider buying and (2) the absence of the big habitual seller (likely has sold out) who had pushed CALC into the 1s.... together these factors supported CALC zooming to the 4s, pushing the RSI to the high 80s. If you check my posts here, my guess was it would hit the 4s before pausing. But as my friend BB noted, there had to be a pullback when you get that overbought. You rarely see a stock have an RSI as high as CALC's got, and virtually never see one where the stock doesn't pullback strongly. The good news is that this deep pullback has brought the RSI down quickly all the way to 52. This gives the stock plenty of room now to make another leg up. Plus, just as the insider buying propelled it and we even saw some insider buying at 3.77/share last week.....that support will come back into play, IMO. So, I think the probability of a jolt back up in short order is highly likely. There are also some strong catalysts just several months away now. JMO

1 · Reply

MrAlientrader Aug. 1 at 4:59 PM

$CALC 80k shares and down 20%? Time to load up

0 · Reply

MUBSN Jul. 31 at 6:22 PM

$CALC interesting......

0 · Reply

MUBSN Jul. 29 at 10:39 PM

$CALC ready again!!!

0 · Reply

MUBSN Jul. 27 at 4:32 PM

$CALC cannot wait to see what happend this week

0 · Reply

Market Cap	38.84M
Revenue (ttm)	0.00
Net Income (ttm)	-13.70M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	23,000
Avg Vol	77,646
Day's Range	N/A - N/A
Shares Out	13.97M
Stochastic %K	64%
Beta	1.33
Analysts	Strong Sell
Price Target	$17.00